MedTrace Logo

The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer

NCT03923335 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 287

Last updated 2019-04-22

No results posted yet for this study

Summary

This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group. The primary endpoint is 5 year disease free survival (DFS).

Conditions

  • Colorectal Neoplasms

Interventions

OTHER

DNA methylation detection

detecting the methylation status of colorectal cancer specimen

Sponsors & Collaborators

  • Sixth Affiliated Hospital, Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Yanxin Luo, MD,PhD · The Sixth Affiliated Hospital, Sun Yat-sen University

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-30
Primary Completion
2021-04-30
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03923335 on ClinicalTrials.gov